Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Evren Yetisir A"'
Autor:
Buyuksimsek M, Togun M, Oguz Kara I, Bisgin A, Boga I, Tohumcuoglu M, Ogul A, Evren Yetisir A, Sahin B, Sumbul HE, Mirili C
Publikováno v:
Balkan Journal of Medical Genetics, Vol 22, Iss 2, Pp 17-24 (2019)
Several studies demonstrated the utility of plasma-based cell-free circulating tumor DNA (ccfDNA) in determination of mutations in non-small cell lung cancer (NSCLC). We aimed to report our results of next generation sequencing (NGS) using liquid bio
Externí odkaz:
https://doaj.org/article/b8150cdb158a48dabd74479f1fe9f638
Autor:
Cem Mirili, Semra Paydas, Ali Ogul, Serkan Gokcay, Mahmut Buyuksimsek, Evren Yetisir, Ismail Hanta, Melek Ergin, Emine Bağır Kılıç, Isa Burak Guney
Publikováno v:
Journal of Oncological Sciences, Vol 4, Iss 1, Pp 56-59 (2018)
Marginal zone lymphoma (MZL) is low grade lymphoma and accounts about 5% of all lymphomas and 5–10% of MZLs are localized in the lung. Interstitial Lung Disease (ILD) is a group of systemic diseases characterized by diffuse inflammation in lung and
Externí odkaz:
https://doaj.org/article/36f74dd0b02343b3a7751fd52b183291
Autor:
Abdullah Evren Yetisir, Semra Paydas
Publikováno v:
Namık Kemal Tıp Dergisi. 9:179-183
Aim: In our study, we aimed to determine the clinicopathological factors affecting the pathological response after neoadjuvant chemotherapy inHER2 positive breast cancer.Materials and Methods: A total of 54 HER2 expression positive cases were include
Autor:
Mahmut Buyuksimsek, Ali Ogul, Abdullah Evren Yetisir, Berna Bozkurt Duman, Mert Tohumcuoglu, Timucin Cil, Tolga Koseci, Mehmet Mutlu Kidi, Hilmi Erdem Sumbul
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311713
Introduction Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor that targets a wide variety of ALK mutations and ROS1 rearrangements. While pancreatic enzyme elevations due to brigatinib are well known, we wanted to present a
Autor:
Isa Burak Guney, Mahmut Büyükşimşek, Abdullah Evren Yetisir, Cem Mirili, İrem Kolsuz, Ali Ogul, Semra Paydas, Mert Tohumcuoglu
Publikováno v:
Turkish Journal of Hematology, Vol 37, Iss 4, Pp 220-225 (2020)
Turkish Journal of Hematology
Turkish Journal of Hematology
Bone marrow infiltration (BMI) affects the stage diagnosis, and treatment of lymphoma. We aimed to evaluate the performance of bone marrow biopsy (BMB) and positron emission tomography-computed tomography (PET/CT) in detecting BMI in lymphoma patient
Autor:
Cem Mirili, Ali Oğul, Mert Tohumcuoğlu, Mahmut Buyuksimsek, Mustafa Toğun, Servet Başdoğan, Semra Paydas, Abdullah Evren Yetisir
Publikováno v:
Anadolu Kliniği Tıp Bilimleri Dergisi. 25:75-80
Amaç: Meme kanseri kadınlarda en sık görülen ve en sık ölüme neden olan kanserdir. Biz de merkezimizde takip ettiğimiz metastatik meme kanseri (MMK) olan hastaların klinik özelliklerini ve tedavi sonuçlarını araştırmak istedik. Gereç
Autor:
Huseyin Can Arbag, Hilmi Erdem Sumbul, Mahmut Buyuksimsek, Ali Ogul, Abdullah Evren Yetisir, Tolga Koseci, Berna Bozkurt Duman, Mert Tohumcuoglu, Oguzhan Kesen, Timucin Cil
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
Introduction The addition of panitumumab to chemotherapy in wild-type metastatic colon cancer contributes to survival. While the skin related side effects of panitumumab are well known, we wanted to present a case where it was a possible cause of acu
Autor:
Ali, Ogul, Semra, Paydas, Figen, Doran, Kivilcim Eren, Erdogan, Mert, Tohumcuoglu, Mahmut, Buyuksimsek, Cem, Mirili, Abdullah Evren, Yetisir
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 26(3)
There are no studies showing PRAME expression in stage II and III colon adenocarcinoma. In this study, we aimed to determine the frequency of PRAME expression and the relationship with survival and clinicopathological data in stage II and III colon a
Autor:
Cem Mirili, Mahmut Büyükşimşek, Ali Ogul, Abdullah Evren Yetisir, Ali Yilmaz, Semra Paydas, Mert Tohumcuoglu
Publikováno v:
Acta Oncologica Turcica. 52:372-378
Publikováno v:
American journal of therapeutics.